Food and Drug Administration： 65 batches of Chinese herbal pieces failed to pass the list of Beijing Tongrentang

　　People’s Daily Online, Beijing, February 6 According to the website of china food and drug administration, a few days ago, the Food and Drug Administration issued a notice on the unqualified 65 batches of Chinese herbal pieces. According to the list of notices, 65 batches of Chinese herbal pieces produced by 61 enterprises failed the inspection, and these 65 batches of Chinese herbal pieces were all licorice pieces. There are many well-known domestic pharmaceutical companies in the list of 61 enterprises, including Beijing Tongrentang, Shizhentang and Jianshengyuan.

　　After inspection by Beijing Institute for Drug Control, 65 batches of Chinese herbal pieces produced by 61 enterprises such as Jiangxi Zhangshu Tianqitang Chinese herbal pieces Co., Ltd. were unqualified. The relevant information is hereby notified as follows:

　　1. Tested by Beijing Institute for Drug Control, Marked as Beijing Guancheng Pharmaceutical Co., Ltd., Hebei Qizhongxin Pharmaceutical Granule Pieces Co., Ltd., Hebei Qiyitang Pharmaceutical Co., Ltd., Hebei Quantai Pharmaceutical Co., Ltd., anguo city Qi ‘ao Chinese Herbal Pieces Co., Ltd., Chifeng Zizhi Chinese Medicine Co., Ltd., Heilongjiang Xiangtai Chinese Herbal Pieces Co., Ltd., Harbin Pharmaceutical Group Shiyitang Chinese Herbal Pieces Co., Ltd., Shanghai Hongqiao Chinese Herbal Pieces Co., Ltd., Jiangsu Huahong Pharmaceutical Technology Co., Ltd. Anhui Jiezhong Biochemistry Co., Ltd., Bozhou Qiancao Pharmaceutical Co., Ltd., Bozhou Huqiao Pharmaceutical Co., Ltd., Bozhou Yonggang Pieces Factory Co., Ltd., Beijing Tongrentang (Bozhou) Pieces Co., Ltd., Jiangxi Pengshi National Medicine Tang Pieces Co., Ltd., Jiangxi Zhangshu Tianqitang Chinese Medicine Pieces Co., Ltd., Jiangxi Zhihetang Chinese Medicine Pieces Co., Ltd., Henan Qingshan Pharmaceutical Co., Ltd., Beijing Shizhentang (Yichang)Pharmaceutical Co., Ltd., Hubei Jingui Chinese Herbal Pieces Co., Ltd., Hunan Jinshitang Chinese Herbal Pieces Co., Ltd., Guangdong Tiantai Pharmaceutical Co., Ltd., Guangxi Guigang Shennong Pharmaceutical Co., Ltd., Guangxi Liuzhou Baicaotang Pharmaceutical Co., Ltd., Guangxi Tongfutang Chinese Herbal Pieces Co., Ltd., Guangxi Yulin Zhizhen Chinese Herbal Pieces Co., Ltd., Guangxi Zhangyitang Chinese Herbal Pieces Co., Ltd., Chongqing Tiankai Pharmaceutical Co., Ltd. Sichuan Boren Pharmaceutical Co., Ltd., Sichuan Jingxin Chinese Herbal Pieces Co., Ltd., Sichuan Xiangru Pharmaceutical Co., Ltd., Sichuan Yuanshangcao Chinese Herbal Pieces Co., Ltd., Chengdu Yicheng Pharmaceutical Co., Ltd., Liangshan Xinxin Chinese Herbal Pieces Co., Ltd., Bazhong Kelun Pharmaceutical Trading Co., Ltd., Guizhou Miaozhiling Pharmaceutical Co., Ltd., Yunnan Xianghui Pharmaceutical Co., Ltd., Shaanxi Xingshengde Pharmaceutical Co., Ltd., Weinan Putaihe Chinese Herbal Pieces Co., Ltd. 63 batches of licorice (licorice tablets) produced by Gansu Guanlan Chinese Herbal Pieces Co., Ltd., Lanzhou Xukang Pharmaceutical Co., Ltd., Zhangye Hengli Chinese Herbal Processing Co., Ltd., Ningxia Northwest Medicinal Materials Technology Co., Ltd., Ningxia Yongshoutang Chinese Herbal Pieces Co., Ltd., Xinjiang Heji Chinese Herbal Pieces Co., Ltd. were unqualified. Unqualified items include character and content determination.

　　After inspection by Beijing Institute for Drug Control, two batches of roasted licorice produced by Shanxi Hunyuan Wansheng Astragalus Development Co., Ltd. and Jiangsu Jianshengyuan Chinese Herbal Medicine Co., Ltd. were unqualified. Unqualified items include character and content determination.

　　Two, the unqualified Chinese herbal pieces, the relevant provincial food and drug supervision and management departments have taken control measures such as seizure, requiring enterprises to suspend sales and use, recall products, and carry out rectification.

　　Third, china food and drug administration requires the provincial food and drug supervision and administration department where the relevant units are located to initiate an investigation on the illegal acts of producing and selling substandard drugs by the above-mentioned enterprises in accordance with Articles 73, 74 and 75 of the Drug Administration Law of People’s Republic of China (PRC), make public the results of the treatment of the relevant units producing and selling substandard drugs within three months, and report relevant information in a timely manner.

　　In the case investigation, if an enterprise has any objection to the authenticity of the product, it can submit it to the local provincial food and drug supervision and administration department, which will investigate and verify the production and sales of the enterprise and inform the provincial food and drug supervision and administration department where the sampled unit is located. The provincial food and drug supervision and administration department where the sampled unit is located shall immediately file an investigation and trace the source of the product after receiving the notice of objection to the authenticity of the unqualified product. If it is indeed produced by the label production enterprise, the relevant provincial food and drug supervision and administration department will give the production enterprise a heavier punishment. (Zhu Jiang)